Five to ten percent of asthmatics can be considered to be affected by severe asthma, a complex and heterogeneous clinical condition that may be influenced by associated disorders that mimic asthmatic symptoms, comorbidities that worsen disease control, possible incorrect inhaler techniques, and/or poor treatment adherence.

In the last ten years, with the introduction of the first available biologic agent for severe asthma in clinical practice, the way of diagnosing and managing the most severe asthma patients dramatically changed from a “one-size-fits-all” approach to a precision medicine one. We are now experiencing a completely new era in the management of severe asthmatic patients, as subjects are clinically and functionally phenotyped to personalize our approach to them.

The aim of this special issue is to summarize the latest knowledge and novel findings in severe asthma pathogenesis, epidemiology, diagnosis, management, and treatment, with particular attention on personalized and precision medicine. We encourage authors to submit original research describing novel findings and review articles summarizing the state of the art on a covered topic.

Potential topics include but are not limited to the following:

• Severe asthma endotypes
• Severe asthma phenotypes
• Treatment adherence and/or correct use/choice of inhalers’ devices
• Psychological impact of severe asthma
• Patient reported outcomes
• Biomarkers to classify severe asthmatics in phenotypes
• Predictive biomarkers for treatment
• Biological therapies
• Immunological approach to severe asthma
• Patients’ perspective
• Epidemiological issues